Apexium Financial LP Has $385,000 Holdings in Abbott Laboratories (NYSE:ABT)

Apexium Financial LP grew its position in Abbott Laboratories (NYSE:ABT) by 30.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,404 shares of the healthcare product maker’s stock after buying an additional 793 shares during the quarter. Apexium Financial LP’s holdings in Abbott Laboratories were worth $385,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Future Financial Wealth Managment LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $31,000. Peterson Financial Group Inc. bought a new position in Abbott Laboratories in the third quarter valued at $32,000. Valued Wealth Advisors LLC increased its stake in Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in Abbott Laboratories during the 3rd quarter worth about $37,000. Finally, JDM Financial Group LLC boosted its stake in shares of Abbott Laboratories by 51.3% during the 3rd quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock worth $41,000 after buying an additional 123 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on ABT. Oppenheimer started coverage on Abbott Laboratories in a research report on Tuesday, October 8th. They set an “outperform” rating and a $130.00 price target for the company. Stifel Nicolaus raised their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Morgan Stanley upped their price target on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 17th. Barclays reissued an “overweight” rating and issued a $158.00 price objective (up previously from $149.00) on shares of Abbott Laboratories in a research report on Monday. Finally, Piper Sandler raised their target price on shares of Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.06.

Abbott Laboratories Stock Up 3.6 %

ABT opened at $129.51 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock has a fifty day moving average of $115.26 and a 200-day moving average of $113.46. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $129.76. The company has a market capitalization of $224.63 billion, a P/E ratio of 16.93, a P/E/G ratio of 2.51 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting the consensus estimate of $1.34. The company had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $11,029,400 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm earned $1.19 earnings per share. On average, equities analysts expect that Abbott Laboratories will post 5.15 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $0.59 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a yield of 1.82%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 30.85%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.